Pfizer Inc.

Key Statistics

Recent News

• Pfizer (PFE): The Best Longevity Stock to Buy Now Insider Monkey

  Pfizer Inc. (NYSE:PFE) is one of the 7 Best Longevity Stocks to Buy Now. On June 8, 2026, Pfizer Inc. (NYSE:PFE) announced that the U.S. FDA approved an expanded indication for Hympavzi to include pat

• What Could Push JNJ Stock Higher From Here? Trefis

  While the market fixates on the STELARA patent cliff, the rest of the business is quietly accelerating. Excluding the legacy drug, Johnson & Johnson (JNJ) grew in double digits for the quarter. The In

• JNJ Raised the Bar: So Why Is the Stock Standing Still? Trefis

  Management raised the bar two months ago, but the stock just shrugged. Here’s why the market is waiting for proof, not promises.

• The Catch Hiding In Eli Lilly Stock's Growth Story Trefis

  Eli Lilly's obesity drug franchise is a juggernaut, but a surprisingly large share of its success relies on price-sensitive consumers.

• These 3 Quality Stocks Will Make You Want to LEAP on Their Calls Barchart

  Thursday’s unusual options activity had plenty to choose from. However, it was the LEAPS that were really worth considering for bullish investors. Of the 28 calls over 365 days, these three quality st

• Can Bristol Myers' Growth Portfolio Offset Legacy Drug Declines? Zacks

  BMY's growth portfolio now drives more than half of revenues, with strong gains from Reblozyl, Breyanzi and Cobenfy helping offset legacy drug declines.

• Pfizer's New Weight-Loss Data Just Gave Eli Lilly and Novo Nordisk Investors Something to Worry About Motley Fool

  The pharmaceutical company's flagship anti-obesity drug continues to bolster its efficacy and tolerability arguments.

• Forget Eli Lilly and Company: As June Volatility Rocks High-Flyers, This Stock Is a No-Brainer Buy 24/7 Wall St.

  Eli Lilly (NYSE:LLY) is the stock everyone wants to own right now, a $1.02 trillion obesity juggernaut that has ripped 20.9% higher in a single month on the back of the GLP-1 mania. But here’s what yo